GlassScriptPhysician profile
Anna Bernice Porter
NPI 1205443561
$1,885.92
in general payments reported to CMS, 2019-2025
13 companies · $800 in 2025
The $800 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $572 · 2024: $514 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,885.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $385.42 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $297.54 | 2023-2025 | Caplyta |
| Boston Scientific Corporation | $268.53 | 2023-2024 | Watchman Access System, Watchman Flx |
| Pfizer INC. | $237.70 | 2023-2025 | |
| Glaxosmithkline, LLC. | $198.35 | 2023-2025 | Trelegy Ellipta |
| Axsome Therapeutics, INC. | $124.99 | 2023 | Auvelity |
| Abbvie INC. | $101.98 | 2024-2025 | |
| Exact Sciences Corporation | $80.50 | 2023-2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $58.16 | 2023-2025 | Invega Sustenna, Xarelto |
| Novo Nordisk INC | $56.20 | 2024-2025 | Ozempic |
| Lilly USA, LLC | $43.17 | 2024-2025 | Mounjaro |
| Vertex Pharmaceuticals Incorporated | $18.61 | 2025 | |
| Phathom Pharmaceuticals, INC. | $14.77 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.